# Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

> **NCT01082549** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 780 (actual)

## Conditions studied

- Squamous Cell Lung Cancer

## Interventions

- **DRUG:** gemcitabine/carboplatin
- **DRUG:** gemcitabine/carboplatin plus Iniparib

## Key facts

- **NCT ID:** NCT01082549
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 780 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082549, "Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01082549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*